Mass-DAC Registry: Drug-Eluting and Bare Metal Stenting in ... Cardiosource, DC - Nov 10, 2008 ... with drug-eluting stents (DES) was associated with decreased mortality and major adverse cardiac events (MACE) compared to bare metal stents (BMS). ...
ASN: CABG Best for Long-Term Benefit in ESRD Patients MedPage Today, NJ - Nov 7, 2008 Three-year survival rates were 42% with CABG, 38.1% with drug-eluting stents, and 34.5% with bare-metal stents, Charles Herzog, MD, of the United States ...
Isotechnika reports second quarter financial results Canada NewsWire (press release), Canada - ... using the CINATRA(TM) voclosporin coated coronary stent system, which will be compared to Atrium's CINATRA(TM) bare metal coronary stent (BMS) platform. ...TSE:ISA
Ask Dr. H: A puzzling aspect of age and a swelling prostate Philadelphia Inquirer, PA - Jul 21, 2008 What we're talking about is a bare metal stent coated with a drug that interferes with clotting at the site. Bare metal stents that prop open plaque-laden ...
Bare metal stent restenosis is not a benign clinical entity - MS Chen, JM John, DP Chew, DS Lee, SG Ellis, DL … - American Heart Journal, 2006 - Elsevier ... 4 However, the bane of baremetalstents is restenosis. Baremetal in-stent restenosis
(ISR) ranges from 15% to 60% depending on patient co-morbidities, vessel ...
A Pooled Analysis of Data Comparing Sirolimus-Eluting Stents with Bare-Metal Stents - C Spaulding, J Daemen, E Boersma, DE Cutlip, PW … - New England Journal of Medicine, 2007 - content.nejm.org ... NEJM 356: 1503-1516 [Abstract] [Full Text]; Serruys, PW, Daemen, J. (2007). Late Stent Thrombosis: A Nuisance in Both BareMetal and Drug-Eluting Stents. ...
Source: Google Scholar
Bare metal stents deliver gene therapy to heart vessels with less inflammation in animal models
Improved materials may allow stents to better deliver beneficial genes to patients with heart disease, by reducing the risk of inflammation that often negates initial benefits.
The new technique, using a compound that binds in an extremely thin layer to bare metal surfaces, may have potential uses in other areas of medicine that make use of metallic implants.
Cardiologists frequently treat heart disease patients by using stents to expand partially blocked blood vessels and improve blood flow. However, new obstructions may gradually form within the stents themselves and dangerously narrow the passageway.
A newer generation of stents releases drugs to counteract this renarrowing process, called restenosis, but the polymer coatings that initially hold the drugs to the stents may stimulate inflammation. The inflammation in turn leads to restenosis.
Researchers at The Children's Hospital of Philadelphia have developed a novel technique to attach therapeutic genes to a stent's bare metal surface. This technique allows the genes to help heal the surrounding blood vessels, while avoiding the inflammation caused by polymer coatings.
The research team reported their proof-of-principle study, using cell culture and animal models, in the early edition of the Proceedings of the National Academy of Sciences, published online this week.
" This is the first study to demonstrate successful delivery of a gene vector from a bare metal surface," said senior author Robert J. Levy, at The Children's Hospital of Philadelphia. A gene vector is a biological substance, in this case an adenovirus, capable of delivering a therapeutic gene to target cells.
Levy's team created a unique water-soluble compound, polyallylamine biphosphonate, that binds to the stent's metal alloy surface in a layer with the thickness of only a single molecule. The biphosphonate holds and gradually releases adenovirus particles of the type used to deliver therapeutic genes.
In cell cultures, the adenovirus successfully delivered genes from alloy samples to animal arterial smooth muscle cells. In a second experiment using rodents, the researchers detected gene expression with significantly lower restenosis in the carotid arteries of animals with the experimental stents, compared to control animals with conventional, polymer-coated stents.
The researchers used a therapeutic gene that encodes for a protein, inducible nitric oxide synthase ( iNOS ), in the carotid artery studies, because of iNOS's ability to control cell damage in blood vessels. "However, in further studies, one might use a combination of therapeutic genes or different gene vectors, for even better results," said Levy.
Metallic implants are already widely used in medicine. Some examples are artificial joints and orthopedic pins and rods, pacemaker electrodes, and titanium tooth implants. "The results of our study may have broader implications for other diseases in which implantable medical devices may be used to deliver gene therapy," said Levy.
